We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+0.59%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
+$34.2M
Cap. Flow
+$31.7M
Cap. Flow %
11.9%
Top 10 Hldgs %
46.64%
Holding
93
New
15
Increased
28
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.95M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$2.53M
3
AUTL
Autolus Therapeutics
AUTL
+$2.24M
4
EPZM
Epizyme, Inc
EPZM
+$2.23M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$2.16M

Top Sells

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$1.59M
2
ADXS
Advaxis Inc
ADXS
+$1.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$884K
4
SVRA icon
Savara
SVRA
+$813K
5
MRSN
Mersana Therapeutics
MRSN
+$603K

Sector Composition

Rank Sector Weight
1 Healthcare 91.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
26
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.88M 1.08%
734,422
+485,715
+195% +$2.53M
QNCX icon
27
Quince Therapeutics
QNCX
$21.5M
$2.78M 1.05%
+327
New +$1.95M
PHAS
28
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.62M 0.99%
200,013
+127,513
+176% +$1.56M
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$2.51M 0.94%
349,996
+71,185
+26% +$806K
PRQR icon
30
ProQR Therapeutics
PRQR
$244M
$2.38M 0.89%
261,521
– –
TBIO
31
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$2.25M 0.85%
+178,306
New +$1.88M
CSII
32
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.2M 0.83%
51,200
-5,000
-9% -$194K
BEAT
33
DELISTED
BioTelemetry, Inc.
BEAT
$2.18M 0.82%
45,300
+10,500
+30% +$552K
EPZM
34
DELISTED
Epizyme, Inc
EPZM
$2.18M 0.82%
+173,536
New +$2.23M
CRBP icon
35
Corbus Pharmaceuticals
CRBP
$165M
$2.06M 0.77%
9,910
-257
-3% -$55K
ARAY icon
36
Accuray
ARAY
$27.5M
$2.03M 0.76%
+524,300
New +$2.12M
FOMX
37
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.92M 0.72%
808,000
– –
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.86M 0.7%
118,314
-5,000
-4% -$68K
ARDX icon
39
Ardelyx
ARDX
$1.24B
$1.83M 0.69%
681,759
+5,000
+0.7% +$15.1K
KDMN
40
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.83M 0.69%
886,177
+129,000
+17% +$287K
INDP icon
41
Indaptus Therapeutics
INDP
$243M
$1.8M 0.68%
186
+16
+9% +$202K
VKTX icon
42
Viking Therapeutics
VKTX
$3.88B
$1.74M 0.65%
209,200
+30,000
+17% +$256K
NVRO
43
DELISTED
NEVRO CORP.
NVRO
$1.7M 0.64%
26,210
-5,000
-16% -$311K
SCYX icon
44
SCYNEXIS
SCYX
$37.4M
$1.67M 0.63%
15,912
– –
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
$1.62M 0.61%
604,884
-16,298
-3% -$48.1K
AUTL
46
Autolus Therapeutics
AUTL
$389M
$1.61M 0.61%
+100,000
New +$2.24M
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.56M 0.59%
410,888
-87,527
-18% -$527K
INGN icon
48
Inogen
INGN
$174M
$1.53M 0.58%
23,000
+13,100
+132% +$997K
NXTC icon
49
NextCure
NXTC
$20.4M
$1.44M 0.54%
+8,008
New +$1.66M
GMDA
50
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.4M 0.53%
+275,000
New +$2.16M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, DAFNA Capital Management held 93 positions worth $266M, up 15% from $232M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $31.7M of net new capital in Q2 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $603K trimmed.

  • DAFNA Capital Management's largest Q2 2019 buy was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.
  • DAFNA Capital Management added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $2.53M increase.
  • DAFNA Capital Management's biggest Q2 2019 reduction was Mersana Therapeutics, cutting an estimated $603K.
  • DAFNA Capital Management fully exited VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019, selling an estimated $1.59M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $266M portfolio in Q2 2019.
  • DAFNA Capital Management opened 15 new positions and closed 6 in Q2 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.